All posts by imreal

Lymphoma Research Foundation Establishes the Kanti R. Rai, MD Clinical Scholar Program for the Ongoing Study of Chronic Lymphocytic Leukemia (CLL)


“This investment in early career scientists will strengthen the pipeline of lymphoma/ CLL research for decades to come and be instrumental in shaping the next generation of CLL experts,” said Meghan Gutierrez, CEO of Lymphoma Research Foundation.

The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization dedicated exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – today announced the creation of the Kanti R. Rai, MD Clinical Scholar program to fund the ongoing study of lymphoma and chronic lymphocytic leukemia (CLL). Established in recognition of Dr. Rai’s global leadership in the field of lymphoma/CLL research and his commitment to LRF’s mission, the first award associated with the program will be announced in Spring 2023.

Dr. Rai has been a global leader in the field of lymphoma/CLL research for more than four decades. The staging system that bears his name was born from his early and groundbreaking work in the field and publication of the Rai prognostic categorization of CLL in a landmark article still used today by physicians and clinical investigators around the world. His research led to the development of several innovative cancer therapies, transforming the way in which CLL is treated. He is currently Professor at The Karches Center for Oncology Research within the Feinstein Institutes for Medical Research at Northwell Health, and is the Joel Finkelstein Cancer Foundation Professor of Medicine and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Elected to LRF’s prestigious Scientific Advisory Board (SAB) in 2007, Dr. Rai has helped to shape LRF’s research portfolio and mentor the next generation of CLL clinicians and scientists.

Each year, LRF will award one participant in its Lymphoma Scientific Research Mentoring Program (LSRMP) with the Kanti R. Rai, MD Clinical Scholar award. As a part of the Foundation’s LSRMP, the awardee will become an LRF Scholar and receive mentoring from world-leading lymphoma experts as they pursue a career in CLL research. The new grant will ensure the awardee’s participation in the two-year program, provide scientific support, and funding for professional development.

“This investment in early career scientists will strengthen the pipeline of lymphoma/ CLL research for decades to come and be instrumental in shaping the next generation of CLL experts,” said Meghan Gutierrez, CEO of Lymphoma Research Foundation. “This level of ongoing support is critical for the study of rare cancers like CLL. The Lymphoma Research Foundation could think of no better way to recognize Dr. Rai’s storied career and leadership in the field of CLL research than through the creation of this new program, which will impact CLL patients here and around the world.”

Share article on social media or email:

Earth’s Edge Wellness Offers Virtual and Holistic Treatment for Eating Disorders


News Image

“Our approach is as eclectic and holistic as it needs to be, yet it is highly detail oriented, as everything is designed intentionally with each client’s specific needs in mind,” says founder Yoni Banayan.

The belief behind Earth’s Edge Wellness’ holistic approach is simple: humans are complex, and everyone has different needs and requires a different approach. Virtual and Holistic eating disorder treatment at this practice looks at the root cause of the eating disorder by reviewing the entire patient as a whole: for example psychological, biological, biophysiological, energetic, financial and spiritual. Since Earth’s Edge Wellness is about soul retrieval, it applies to practice, practitioner, company and client. If food or body issues are getting in the way of what individuals truly value, including spirituality and experiencing life deeper, then-current conscious awareness can help in healing. The therapy and coaching Earth’s Edge Wellness offers is highly somatic, spiritual, experiential and fun. Their team is global, ranging from staff in Australia to New York and California. Part of the benefit of having diverse staff members, aside from the broad techniques and ideas being generated, is the fact that they are available at various times of the day and can generally make almost any time work. Earth’s Edge Wellness’s dietitian is not only a specialist in eating and exercise disorders but also in sports nutrition, so she will also help factor in particular physical goals or aspirations. Their team of spiritual healers have extensive experience and knowledge. They have been providing teachings to thousands of people on techniques from Buddhist, Sufi and Kundalini traditions. Earth’s Edge Wellness can also provide an experiential career coach with +40 years of experience who helps clients discover passions and finds a way to actualize that passion outward as opposed to inward. Earth’s Edge Wellness is so sure about their program that if clients are not happy within the first week, they will happily offer a refund.

“Our approach is as eclectic and holistic as it needs to be, yet it is highly detail oriented, as everything is designed intentionally with each client’s specific needs in mind,” says founder Yoni Banayan.

More About Earth’s Edge Wellness:

Earth’s Edge Wellness’ approach is very simple. They talk to clients and see what help is needed. They then gather their team of people with the skill sets and personalities that will help clients get to a place where food, body or exercise are sources of joy instead of pain. They also directly address concerns that clients have by using techniques that involve the body as well as the unconscious mind. Earth’s Edge Clients choose their own treatment modalities and ideal treatment team based on a schedule that works for them. With Earth’s Edge Wellness, those with disordered eating can create a long-term support system to get back to living life. For more information, please call 702-582-9474 or visit http://www.earthsedgewellness.com.

Share article on social media or email:

Standard Process Donates 67,000 Meals Through its 7th Annual One Day, One Bottle, One Meal Event


News Image

“One Day, One Bottle, One Meal shows what is possible when we come together and collaborate for a wonderful cause” said Standard Process President and CEO Charlie DuBois.

Standard Process® has announced the donation of 67,000 meals to a network of more than 200 food banks across the nation as part of the company’s ongoing commitment to change lives through whole food nutrition. The donation — which supported Feeding America® — was made possible through the company’s 7th annual One Day, One Bottle, One Meal event, which was held on Thursday, August 4, 2022.

“One Day, One Bottle, One Meal shows what is possible when we come together and collaborate for a wonderful cause” said Standard Process President and CEO Charlie DuBois. “We appreciate all of our customers and employees who understand the power of whole food nutrition and continue to help us change lives.”

Standard Process has donated one meal for every Standard Process, MediHerb®, and Standard Process Veterinary Formulas™ product sold since the one-day event launched in 2016. The effort has resulted in more than 444,000 donated meals to help fight hunger across the country.

###

About Standard Process

Standard Process is a third-generation, family-owned company that has been a leader in making whole food-based supplements since 1929. From the company’s certified organic farm at its Palmyra, Wisconsin headquarters to the Nutrition Innovation Center in Kannapolis, North Carolina, Standard Process is committed to clinical science that advances health and changes lives through whole food-based nutrition.

Learn more about Standard Process and find a health care professional who sells company products at: https://www.standardprocess.com/

Share article on social media or email:

Groundbreaking Study Finds C15:0, an Emerging Essential Fatty Acid, is Key to Unlocking the Second-Ever Discovered Full-Acting Endogenous Cannabinoid


A recently published peer-reviewed study in Nature’s Scientific Reports revealed that an emerging essential fatty acid, called C15:0, is used by our bodies to make the second-ever discovered full-acting endocannabinoid.

Endocannabinoids have been touted as the holy grail to health due to their numerous health benefits, including reducing inflammation, controlling pain, lowering anxiety, improving sleep, and supporting cognition and brain health.

“The scientific world has been actively searching for molecules within our bodies that naturally regulate the endocannabinoid system,” said Dr. Stephanie Venn-Watson, the study’s lead author and co-founder and CEO of Seraphina Therapeutics. “The discovery of pentadecanoylcarnitine as the world’s second full-acting endocannabinoid opens an exciting new path to broadly and safely supporting both physical and mental health.”

In this groundbreaking study funded by the Office of Naval Research, pentadecanoylcarnitine (PDC) was identified as a key molecule that is made within our bodies’ cells by combining C15:0 with carnitine. When tested for potential therapeutic activities, it was discovered that PDC fully activated CB1 and CB2 receptors that are present in the human endocannabinoid system.

An endocannabinoid is a molecule that is naturally intended to activate CB1 and CB2 receptors and is endogenous, which means it is made by our body. This is different from exogenous cannabinoids, like cannabis, which are put into our body and can artificially trick our CB1 or CB2 receptors.

Prior to this discovery, only one endocannabinoid, called 2-arachidonoylglycerol (2-AG), had been known to fully target both CB1 and CB2 receptors. 2-AG is made using an omega-6 fatty acid called arachidonic acid. As a key limitation, however, 2-AG is rapidly metabolized and has a very short half-life. While Venn-Watson’s paper suggests that PDC is a more stable and longer lasting metabolite, more studies are needed.

In addition to showing that a diet higher in C15:0 results in raised PDC levels, the current study demonstrated that PDC has direct, broad, and dose-dependent beneficial effects on multiple human cell-systems mimicking various disease states. PDC effectively lowered ten pro-inflammatory cytokines in systems relevant to inflammatory, autoimmune, cardiovascular, neoplastic, pulmonary, and skin diseases.

“Given our growing understanding of C15:0 as an essential fatty acid, it makes perfect sense that C15:0 is used to make active and beneficial metabolites in our bodies,” said Dr. Stephanie Venn-Watson. “The understanding that we can increase our PDC levels by increasing our C15:0 intake provides a tangible path to better health.”

Venn-Watson’s team had previously discovered C15:0 as the first essential fatty acid to be found in 90 years, which was published during May 2020 in Nature’s Scientific Reports. Since then, over 30 peer-reviewed studies have been published from institutions around the world linking higher C15:0 to lower risks of multiple chronic conditions, including type 2 diabetes, heart disease, heart failure, and nonalcoholic fatty liver disease. At least two studies have associated higher circulating C15:0 to longer lifespan, and a second team corroborated odd-chain saturated fatty acids, including C15:0, as essential fatty acids.

The surprising discovery of C15:0 as an essential fatty acid, which was made while Venn-Watson was studying how to continually improve the health and welfare of aging Navy dolphins, was recently featured as a TEDx San Diego talk and as a Fast Company World Changing Idea. “The dolphins were the first to teach us that C15:0 is a healthy nutrient in an all-fish diet, more so than omega-3s,” said Venn-Watson. “We now have dolphins to thank for this latest discovery, which is gearing up to be a game-changer to help people lower anxiety, improve sleep, and manage pain.”

###

About Seraphina Therapeutics. Inc.

Seraphina Therapeutics, Inc. is a health and wellness company dedicated to advancing global health through the discovery of essential fatty acids and micronutrient therapeutics. Through rigorous breakthrough science, the company develops pure and essential nutrients to support cellular health and counter age-related breakdown. With its team of industry-leading scientists, Seraphina Therapeutics challenges long-held approaches to nutrition, enabling the creation of novel health products designed to support quality of life. The company is a spinout of Epitracker, Inc., headquartered in San Diego. For more information, please visit seraphinatherapeutics.com and fatty15.com.

Share article on social media or email:

The DRIPBaR Launches in Buford Georgia August 29th, 2022


Catherine and Lizelle Owners of The DRIPBaR Buford GA

Catherine and Lizelle Owners of The DRIPBaR Buford GA

The DRIPBaR is excited to announce the opening of their newest location in Buford, Georgia on August 29th, 2022.

The DRIPBaR is excited to announce the opening of their newest location in Buford, Georgia on August 29th, 2022. This marks the newest location for the franchise, with approximately 500 additional locations in the pipeline. The DRIPBaR Buford will offer all of the standard DRIPBaR services, such as IV vitamin therapy and IM Quick Shots. This particular location will also offer Halotherapy, a cutting-edge salt therapy that promotes detoxification, improves respiratory health, and improves immune resilience, along with an Infrared Sauna.

Longtime locals Lizelle Kruger and Catherine Getz own and operate The DRIPBaR in Buford, and are excited to bring cutting-edge IV therapy and additional wellness services to Buford and the surrounding communities.

Customers will have a variety of IV Lifestyle & IV Health Support Drips to choose from, including the popular Powerpack, Allstar, and Restoration Drips. All of these services are designed to help customers look and feel their very best – whether they are looking for a quick boost or a more long-term wellness solution. For those who don’t have time for a full vitamin infusion but want the benefit, clients can choose one of five IM Quick Shots that give the body an immediate added boost.

Designed to offer quick doses of powerful and optimally-balanced nutrients and formulas, The DRIPBaR’s infusions are popular for boosting energy, hydrating, detoxing from chemicals and toxins, improving overall health and vitality, and addressing more specific wellness needs. All of the IV infusions at The DRIPBaR Buford are administered by highly trained nurse practitioners and registered nurses in a safe, comfortable, and welcoming day spa environment.

To celebrate their arrival, The DRIPBaR Buford is offering 50% off any IV drip plus a FREE B12 Quick Shot on your first visit. Appointments can be booked here!

Share article on social media or email:

United Breast Cancer Foundation Participates in the 2022 CFC Season!


News Image

“Some people might say it takes an extraordinary person to care enough to give, but it’s more common than you think. Anyone can be a change-maker through the CFC.”

This year, United Breast Cancer Foundation (UBCF) is excited to announce its tenth consecutive year participating in the Combined Federal Campaign (CFC). The CFC is an opportunity for Federal, Military, and Postal workers and retirees to donate to their choice of local or international charity. The CFC campaign will run from September 1, 2022, through January 15, 2023. United Breast Cancer Foundation’s CFC number is 77934.

This year’s CFC tagline is “You Can Be the Face of Change”. Since its inception, the CFC has raised more than $8.6 billion for charities and people in need. The CFC shares, “Some people might say it takes an extraordinary person to care enough to give, but it’s more common than you think. Anyone can be a change-maker through the CFC.”

CFC donors who contribute to UBCF directly help breast cancer patients, survivors, and their families. Donors can give various amounts per bi-weekly pay period. By giving $50 per pay period, donors can help a patient who is struggling to pay their rent and afford treatment. Contributing $25 per pay period can pay for holistic treatments or self-care necessities. A one-time gift of $150 will cover the cost of a breast screening. Regardless of how much is donated, contributions will have a positive impact on the lives of those fighting breast cancer.

UBCF is proud to be a CFC approved, GuideStar platinum, and Charity Navigator 3-star rated charity. CFC approved charities are 501(c)(3) organizations and have confirmed eligibility through a meticulous application process. Most organizations that participate in the CFC are also members of National Federations. UBCF is a member of the Creating Healthier Communities(CHC) Federation.The CHC Federation works to address the barriers to good health and equity. Federations such as CHC have certain standards which their members must uphold.This high standard of excellence results in a group of charities that donors can confidently support.

Taylor is a UBCF client living in Texas with her husband and child. Based on their household income, she was turned away by several organizations when searching for assistance. She has suffered through complications and a severe infection after her breast surgery. Her work hours were reduced and her husband picked up double shifts to try to make ends meet. Taylor has been trying to prepare mentally, physically, and financially for her next surgery which will take place hours away from home.

Thanks to donations from generous supporters, UBCF awarded Taylor a substantial Individual Grant to cover a mortgage payment and two large utility bills. With gratitude, she shared, “Omg, I can’t believe it! I’m so thankful for this. I was so stressed wondering how we were going to pay the bills. I really appreciate this! I am in tears right now, but they are tears of joy…”

Please consider supporting UBCF through the CFC – choose charity #77934. Donate using the link https://givecfc.org/home. With the help of generous contributions from the CFC, UBCF is able to help deserving people like Taylor. UBCF thanks you for your service and support!

About UBCF: UBCF is committed to offering breast health and wellness services focused on cancer prevention, screening, treatment, and overall wellness. UBCF’s mission is to make a positive difference in the lives of those affected by breast cancer and does so through seven life-supporting patient and family programs available to women, men, and families nation-wide. UBCF never denies services to anyone regardless of age, race, gender, ethnicity, income or medical insurance coverage. Tax-deductible contributions may be made towards UBCF’s programs. UBCF accepts Donor Advised Funds and vehicle and property donations as well. Combined Federal Campaign #77934. https://www.ubcf.org

Share article on social media or email:

For the third consecutive year, Solara Labs honored on Inc. Magazine’s Inc. 5000 list


“I am so proud of our team and feel honored to continue bringing our quality-centric, science-based approach to an ever-growing population of health-conscious consumers.” – Dr. Jose Rocca, Founder & CEO

Solara Labs, an innovator in the development, manufacture, and branding of dietary supplements, is proud to announce it has again been recognized among America’s fastest-growing private companies on this year’s Inc. 5000 list. This is the third consecutive year the company has made the annual ranking.

Solara Labs’ revenue grew 129% between 2018 and 2021, which reflects the significant growth in the company’s advanced manufacturing business and consumer packaged goods (CPG) vitamin brands, which it markets through E-Commerce channels.

Published annually by Inc. magazine, the Inc. 5000 lists the most prestigious ranking of the fastest-growing private companies in America. The list represents a one-of-a-kind look at the most successful companies which puts Solara Labs in an elite group of companies spanning all industries.

Solara Labs is the 127th highest ranked company in the South Florida region, which includes the area from Miami to West Palm Beach.

Founded in 2007 by pharmaceutical scientist Dr. Jose Rocca, Solara Labs set out to bring innovative products and a science-based approach to the dietary supplement industry. It is perhaps best known for its proprietary “fast-melt” technology, which enables health-conscious consumers to enjoy supplemental nutrition without swallowing pills and without the high-sugar content found in other popular delivery formats.

The company not only develops and manufactures unique products for top companies in the health and wellness industry, it also touts its own successful vitamin brands. These include EZ Melts® for the general vitamin consumer, BariMelts® for weight-loss-surgery patients, Renzo’s® for children, and the soon to be launched Prominent Nutrition®, which will feature premium botanical and mineral formulations.

“Once again I am honored to see Solara featured on the Inc. 5000 list. Our success through the years is due to the contributions of our team members and enhanced by the loyal support of my family, which has been part of this entrepreneurial journey every step of the way. I speak on behalf of our whole Solara family when I say how blessed we are to be part of the lives of the tens-of-thousands of people who count on us every day to support their health needs. I am so proud of our team and am excited to continue bringing our quality-centric, science-based approach to an ever-growing population of health-conscious consumers,” said Solara Labs Founder and CEO, Dr. Jose Rocca, Ph.D., R.Ph.

“I’m proud to see the hard work of our growing team contribute to yet another year of success. It is an honor to serve a company that puts its customers first with science-based, quality products that people love having as part of their daily regimen. I’m thrilled for Dr. Rocca and all my teammates as we embark into a new chapter of growth and excitement for the future,” said Tim Berthold, Chief Marketing Officer.

“Solara continues to innovate not only with unique products that customers love, but with approaches to quality and scientific expertise that are becoming more valued every day in our industry and among consumers at large. I’m so happy for the team and to be a part of continuing our path on the leading edge of innovation in our industry,” remarked Dr. David Mastropietro, PhD, Vice President of Product Management and Regulatory Affairs.

The Top 500 companies on the list are featured in the September issue of Inc. magazine.

About Solara Labs:

Solara Labs is a boutique manufacturer of vitamins and other dietary supplements, headquartered in Miami, Florida. The team has over 100 years of experience in pharmaceutical and nutraceutical development and also markets CPG vitamin brands of its own, including EZ Melts®, BariMelts®, Renzo’s®, and Prominent Nutrition®. Founded by pharmaceutical-development expert Dr. Jose Rocca, Solara Labs is a specialist in the development of complex formulations for the industry, which includes its proprietary “fast-melt” delivery technology.

For more information, please visit http://www.solaralabs.com.

Share article on social media or email:

Dr. Rod J. Rohrich Recognized by Newsweek as the Best Rhinoplasty Surgeon in the United States for the Second Consecutive Year


Dr. Rod J. Rohrich selected as the top rhinoplasty surgeon in the United States by Newsweek

Dr. Rod J. Rohrich selected as best rhinoplasty surgeon in the United States by Newsweek

I’m extremely honored to have been recognized by Newsweek in this peer reviewed process. These types of awards are valuable tools that can help guide patients towards well qualified plastic surgeons.

Renowned rhinoplasty specialist, Dr. Rod J. Rohrich was recently ranked as the best rhinoplasty surgeon in the United States for the second consecutive year in Newsweek’s recently published peer reviewed list of top performing plastic surgeons.

Partnering with Statista Inc., Newsweek has published a ranked list of the best plastic surgeons in the United States in each of five different surgical categories of the most common cosmetic surgery procedures of breast augmentation, liposuction, blepharoplasty, facelifts, and rhinoplasty.

The ranked lists were the result of an independent national survey of doctors, surgeons, plastic surgery clinic managers, and health care professionals in plastic surgery generating over 5,900 recommendations. Each candidate on the list was given an associated quality score based on that surgeon’s expertise, surgical process, post-operative follow-up care, surgical outcomes, and overall quality of care provided by the candidate.

The survey identified 349 plastic surgeons which were then ranked into lists of the top 150 in each of the five specialties, with the specific rankings based on their final quality score.

Dr. Rohrich was ranked in the first position at number 1 for best rhinoplasty surgeons in the United States, with the top score of 94.64% based on the scoring system. Dr. Rohrich also appeared in the other lists, ranking number 1 in facelifts, number 3 in liposuction, number 4 in blepharoplasty, and number 6 in breast augmentation. Dr. Rohrich also ranked number 1 in both rhinoplasty and facelifts on 2021 list.

“I’m extremely honored to have been recognized by Newsweek in this peer reviewed process,” says Dr. Rohrich. “These types of awards are valuable tools that can help guide patients towards well qualified plastic surgeons as surgeon selection is the single most important factor for ensuring a successful outcome in plastic surgery.”

A long-standing advocate for patient safety, Dr. Rohrich lectures frequently around the world at surgical conferences and educational meetings promoting innovations in safe and effective plastic surgery practices. Much of his writing and presentations focus on rhinoplasty, and revision rhinoplasty, that is, correcting previously performed rhinoplasties that have had poor outcomes. Dr. Rohrich is also the author of the authoritative textbooks on the subject, “Dallas Rhinoplasty: Nasal Surgery by the Masters” which is now published in six languages.

“Rhinoplasty truly epitomizes plastic surgery as a whole because it is a surgery of such great finesse and takes years to master,” says Dr. Rohrich. “Patients should always do their research and choose their surgeon carefully. Make sure he or she is board certified by the American Board of Medical Specialties, and has the expertise and the experience to deliver a safe and satisfactory outcome.”

About Rod J. Rohrich, M.D., F.A.C.S.

Dr. Rod J. Rohrich is a board certified plastic surgeon in Dallas, Texas. He is considered one of the most influential surgeons in this century. He was named the top plastic surgeon in America by Newsweek in both rhinoplasty and facelift surgery in 2021 and 2022. Dr. Rohrich is a Clinical Professor of Plastic Surgery at Baylor College of Medicine. He was the first Chair of the Department of Plastic Surgery as well as the first plastic surgeon selected as a Distinguished Teaching Professor at UT Southwestern Medical Center. He graduated from Baylor College of Medicine with high honors, and completed his plastic surgery training at the University of Michigan Medical Center and fellowships at Massachusetts General Hospital/Harvard (hand/microsurgery) and Oxford University (pediatric plastic surgery). He is Chair of the Dallas Rhinoplasty Meeting, Founding Chair of the Dallas Cosmetic Surgery and Medicine Meeting, Founding Member of the Alliance in Reconstructive Surgery, and a Founding Partner of the Dallas Plastic Surgery Institute.

He is the immediate past (after serving for 18 years) Editor-in-Chief of the most respected global peer reviewed plastic surgery journal – the Plastic and Reconstructive Surgery Journal. He is Founding Editor-in-Chief/Editor Emeritus of the first open access peer reviewed plastic surgery journal, PRS Global Open. Dr. Rohrich has published over 1000 peer reviewed articles and seven textbooks in plastic surgery including a best-selling medical book entitled The Facial Danger Zones. Dr. Rohrich recently published an innovative cosmetic surgery video atlas, Cosmetic Surgery by the Masters.

Dr. Rohrich also served as president of the American Society of Plastic Surgeons (ASPS), the largest organization of board certified plastic surgeons in the world. He repeatedly has been selected by his peers as one of America’s best doctors. He received the ASPS Special Achievement Award and on three occasions has received one of his profession’s highest honors, the Plastic Surgery Foundation (PSF) Distinguished Service Award, which recognizes his contributions to education in plastic surgery. In addition, he has also been recognized by the PSF with the Plastic Surgery Foundation Distinguished Career Researcher Award for his contributions to plastic surgery research and innovations.

Share article on social media or email:

Announcing the Human Animal Bond Innovation Award Winners


News Image

The three winners are not only offering valuable programs to build the human-animal bond, they are also setting an example for those that want to create a more pet-friendly world.

The Human Animal Bond Research Institute (HABRI) today announced the winners of the inaugural Human Animal Bond Innovation Awards, which recognizes companies and organizations with innovative products and programs designed to advance the human-animal bond and create a more pet-friendly society.

“As the Presenting Sponsor for the Human Animal Bond Innovation Awards, PetSmart Charities is proud to celebrate organizations that have gone above and beyond to strengthen the connection between people and pets,” said Aimee Gilbreath, President of PetSmart Charities. “This year’s honorees support the deep integration of pets into people’s lives, and their efforts will make a difference for many pets — and those who love and care for them.”

Nominations were selected by an expert committee of pet care community leaders assembled by HABRI. Winners were honored at a special awards ceremony held in conjunction with the annual SuperZoo show in Las Vegas. The 2022 Human Animal Bond Innovation Award winners are:

Product & Service Category: Health Alliance Medical Plans

Health Alliance Medical Plans offers health insurance plans across multiple states in the Midwest region of the United States. As of January 2022, Health Alliance Medical Plans became the first human insurance company to provide fully-paid access to 24-hour veterinary telehealth for 30,000 Medicare Advantage plan members in three regional offerings.

“It’s a fact that pets play a tremendous role in human well-being,” said Heidi Sirota, President and Chief Pet Officer of Nationwide’s pet insurance division. “As a proud sponsor of HABRI’s Innovation Awards, Nationwide applauds Health Alliance Medical Plans for advancing the human-animal bond by making critical health resources available to pet families.”

Workplace Culture Category: American Heart Association

The American Heart Association’s Best Friend Fridays campaign is part of the Association’s Healthy Bond for Life initiative to raise awareness about the physical and mental health benefits of pet companionship. Each Friday throughout the summer, American Heart Association employees are encouraged to talk about their pets, share photos, welcome pets on video calls, take breaks with their pets, and more, all with the goal of normalizing pet ownership and pet-friendly workplaces. As a way to spread the message far and wide, the American Heart Association provides valuable resources for companies and organizations to implement their own workplace Best Friend Fridays.

“As the Workplace Culture Award Sponsor, Zoetis was inspired to see the nominees going above and beyond to support the human-animal bond in the workplace, and we are honored to recognize the outstanding winner,” said Dr. Oliver Knesl, BSc BSc (Hons) MSc BVSc MRCVS CSAM, Executive Director, U.S. Diagnostics, Veterinary Professional Services at Zoetis. “The American Heart Association’s Best Friend Fridays program encourages pets to be a part of their employees’ workday on a weekly basis, and goes one step further by educating employees about the many science-based health benefits of the human-animal bond.”

Public Service Category: Pet Peace of Mind

Pet Peace of Mind is the only national program providing a care model for the pets of seriously ill patients in hospice, including helping pets find a loving new home when necessary. Pet Peace of Mind’s program trains hospices to support each patient’s pet care needs in practical ways by deploying trained local volunteers. Each year, Pet Peace of Mind programs serve more than 3,500 patients and meet the needs of 4,000 pets across the United States, responding to an essential need for this type of support.

“We were impressed with the innovation, commitment and compassion of all of the nominees for the first Human Animal Bond Innovation Awards,” said Steven Feldman, president of HABRI. “The three winners are not only offering valuable programs to build the human-animal bond, they are also setting an example for those that want to create a more pet-friendly world.”

HABRI also recognizes Supporting Sponsors, Wellness Pet Company, Morris Animal Foundation and the World Pet Association, who together helped bring this inaugural recognition program to fruition.

“Wellness Pet is a proud sponsor of HABRI’s Human Animal Bond Innovation Awards, which is such a wonderful opportunity to recognize and celebrate companies and organizations that aren’t necessarily in the pet care space, but who are doing great work to support the human-animal bond,” said Chanda Leary-Coutu, Director, Consumer Experience, Wellness Pet Company.

###

About HABRI

HABRI is a not-for-profit organization that maintains the world’s largest online library of human-animal bond research and information; funds innovative research projects to scientifically document the health benefits of companion animals; and informs the public about human-animal bond research and the beneficial role of companion animals in society. For more information, please visit http://www.habri.org.

Share article on social media or email:

VeraDermics Inc. Secures Licensing of First-in-Class Antiviral Targeting the Treatment of Molluscum Contagiosum and other Poxviruses


News Image

VeraDermics Incorporated, developer of drugs for dermatology, today announced that it has entered into a definitive license agreement with the University of Pennsylvania (Penn) for patent rights covering a newly developed compound for the specific treatment of molluscum contagiosum developed by Penn and Fox Chase Chemical Diversity Center, Inc. (FCCDC) – adding to VeraDermic’s growing dermatology portfolio. The lead compound identification reflects nearly a decade of research by leading experts in poxvirus replication led by Robert Ricciardi, Ph.D., Chair of Basic and Translational Sciences at the University of Pennsylvania School of Dental Medicine, and Allen Reitz, Ph.D., Chief Executive Officer, and Rick Scott, Ph.D., VP, Research, of FCCDC.

The lead pre-clinical compound, VDMC-7269, is a potent replication inhibitor designed to block the poxvirus that causes molluscum contagiousum. The licensing of VDMC-7269 demonstrates VeraDermics’ continued commitment to dermatology and to targeting dermatologic conditions lacking in FDA approved therapeutics. VeraDermics intends to bring VDMC-7269 to the clinic with molluscum contagiosum as the lead indication for development.

“As a dermatologist, molluscum contagiosum is one of the most frustrating-to-treat conditions that I encounter in my clinical practice,” said Tim Durso, M.D., President and Chief Executive Officer of VeraDermics. “Molluscum primarily affects young children, and many existing treatment options are poorly tolerated by this patient population. If approved, an effective topical treatment for molluscum contagiosum could result in a paradigm shift in the treatment of this condition which affects millions of patients every year.”

Molluscum contagiosum affects approximately 6 million Americans, the majority of whom are younger than 14 years of age. It is one of the most common reasons that children visit a pediatric dermatologist. Despite its prevalence, there are no FDA-approved prescription treatments for the condition. While existing treatments are often designed to be locally destructive (e.g. cryotherapy, cantharidin) or utilize non-specific antiviral properties, VDMC-7269 is specifically designed to target molluscum virus replication. Targeting a specific protein in the molluscum viral replication process that is structurally distinct from its human counterpart is expected to give VDMC-7269 a wide therapeutic window when treating patients.

“We have been working on developing novel antivirals for the treatment of the poxviruses such as molluscum contagiosum together with Prof. Robert Ricciardi of the University of Pennsylvania since 2014,” said Allen Reitz, P.h.D., Chief Executive Officer of FCCDC. “This work includes the discovery of VDMC-7269, whose activity is particularly exciting because it represents a defined molecular target to treat the disease. Preclinical data suggest VDMC-7269 is a potent inhibitor of viral replication and is suitable for topical use. We are very excited that VeraDermics will advance this program further because molluscum contagiosum is currently undertreated and represents a large commercial opportunity.” Dr. Rick Scott of FCCDC was the Principal Investigator on the key Phase II Small Business Innovation Research Grant (SBIR) grant from the NIH that enabled the successful completion of this project, including the discovery of VDMC-7269.

“The discovery of VDMC-7269 involved identifying a novel method for screening this drug as well as using genetic and structure-guided approaches coupled with medicinal chemistry to identify and target a protein essential for replication of molluscum contagiosum virus,” says Dr. Ricciardi “This work entailed the talents and strong collaboration of scientists from both the University of Pennsylvania and FCCDC. I am very pleased that VeraDermics, with its dedication and strong expertise in dermatological drugs, will be moving the development of VDMC-7269 in the direction of clinical application.”

By adding VDMC-7269 to its pipeline, VeraDermics aims to create a best-in-class treatment for molluscum contagiosum.

“The poxvirus antiviral development program is the perfect addition to VeraDermics’ existing dermatology pipeline, and is consistent with our team’s vision to leverage our end-user knowledge as board-certified dermatologists to identify therapeutics that address key unmet needs in our field,” said Reid Waldman, M.D., Chief Operating Officer at VeraDermics. “If approved, this product candidate and the remainder of our pipeline can benefit from the synergy of a shared salesforce in dermatology. We are very excited to have the opportunity to develop such a promising asset based on nearly a decade of hard work from our colleagues at the University of Pennsylvania and Fox Chase Chemical Diversity Center.”

Research that led to the development of licensed patent rights was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R44AI125005 and R41AI162385.

About VeraDermics Inc.:

VeraDermics Inc. is a dermatology-focused pharmaceutical company with a pipeline of patient-friendly therapeutics aimed at helping individuals affected by skin diseases. VeraDermics portfolio includes therapeutics addressing common warts, genital warts, alopecia areata, molluscum contagiosum, and beyond . Find out more at http://www.veradermics.com.

About Fox Chase Chemical Diversity Center:

Fox Chase Chemical Diversity Center, Inc. (FCCDC) is based in Doylestown, Pennsylvania, USA at the Pennsylvania Biotechnology Center and is affiliated with the Pennsylvania Drug Discovery Institute (PDDI). FCCDC conducts early-stage drug discovery research including target validation, medicinal chemistry, in vitro pharmacology, and ADME characterization. FCCDC’s goal is to transition innovative biomedical research technologies into fully-fledged drug discovery and development programs for evaluation in human clinical trials and eventual commercialization. Please visit fc-cdci.com.

Share article on social media or email: